New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 28, 2014
05:13 EDTCTICCTI announces GOG completes enrollment in Phase 3 trial of paclitaxel poliglumex
Cell Therapeutics announced that the Gynecologic Oncology Group, or GOG, informed CTI that it has completed patient enrollment in the GOG-0212 Phase 3 clinical trial of investigational agent paclitaxel poliglumex as maintenance therapy in ovarian cancer. The trial is being conducted and managed by the GOG, which is one of the National Cancer Institute's funded cooperative cancer research groups focused on the study of gynecologic malignancies.
News For CTIC From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 29, 2014
16:18 EDTCTICCTI BioPharma raises FY14 operating loss view to $66M-$71M from $45M-$50M
As a result of the stock issuance in the transaction described above with Chroma resulting in an expense recognition of approximately $21M, CTI has revised its financial guidance such that non-GAAP operating loss for 2014 is now expected to range from approximately $66M-$71M rather than $45M-$50M as previously expected, which excludes non-cash share-based compensation expense.
16:16 EDTCTICCTI BioPharma reports Q3 EPS 3c, consensus (3c)
Reports Q3 revenue $39.53M, consensus $24.3M.
October 27, 2014
05:14 EDTCTICCTI BioPharma acquires exclusive worldwide license to tosedostat
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use